Effect of perioperative tamsulosin on successful ureteral access sheath placement and stent-related symptom relief: A double-blinded, randomized, placebo-controlled study.
| Autor: | Nam KH; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Suh J; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Shin JH; Department of Urology, Ewha Womans University Mokdong Hospital, Seoul, Korea., Chae HK; Department of Urology, Gangneung Asan Medical Center, University of Ulsan College of Medicine, Gangneung, Korea., Park HK; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. hkpark@amc.seoul.kr. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Investigative and clinical urology [Investig Clin Urol] 2024 Jul; Vol. 65 (4), pp. 342-350. |
| DOI: | 10.4111/icu.20240005 |
| Abstrakt: | Purpose: This study investigated the effect of administering tamsulosin before surgery on the successful insertion of a 12/14 French (F) ureteral access sheath (UAS) during the procedure, as well as the impact of preoperative and postoperative tamsulosin use on symptoms related to the ureteral stent. Materials and Methods: This study was a randomized, single-center, double-blinded, placebo-controlled trial involving 200 patients who underwent unilateral retrograde intrarenal surgery. Patients received either tamsulosin (0.4 mg) or placebo 1 week before surgery until stent removal. Patients were randomly assigned to one of four groups. Group 1 received tamsulosin throughout the study period. Group 2 received tamsulosin before surgery and placebo after surgery. Group 3 received placebo before surgery and tamsulosin after surgery. Group 4 received placebo before and after surgery. The USSQ (Ureteral Stent Symptom Questionnaire) was completed between postoperative days 7 and 14 immediately before stent removal. Results: A total of 160 patients were included in this analysis. Their mean age was 55.0±11.0 years, and 48 patients (30.0%) were female. In the group that received preoperative tamsulosin, the success rate of 12/14F UAS deployment was significantly higher than that of the preoperative placebo group (88.0 vs. 75.3%, p=0.038). Preoperative and postoperative tamsulosin did not significantly alleviate symptoms related to the ureteral stent. Conclusions: Our results revealed that preoperative administration of tamsulosin improved the success of larger-sized UAS, whereas preoperative and postoperative tamsulosin use did not significantly alleviate symptoms related to ureteral stents. Competing Interests: The authors have nothing to disclose. (© The Korean Urological Association.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|